Streetbeat News

Products Services

AAPL

HNHPF

Foxconn Technology Group is expected to have a strong October due to orders for Apple's M3-powered new MacBook Pro and iMac. Foxconn is also responsible for components such as chassis.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:15 pm

ADAP

Adaptimmune Therapeutics (NASDAQ:ADAP) has reported positive outcomes for patients with synovial sarcoma who received afami-cel in the SPEARHEAD-1 trial. The trial showed a 39% clinical response rate with a median duration of response of 12 months. The median overall survival was 17 months, compared to a historical median of less than 12 months for patients who received two or more prior lines of therapy. Adaptimmune is on track to make afami-cel its first commercial product, with the completion of the Biologics License Application (BLA) targeted for Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:14 pm

RHHBY

SRPT

Sarepta Therapeutics Inc (NASDAQ:SRPT) released topline results from its Phase 3 study of Elevidys, a gene therapy for Duchenne muscular dystrophy. The results showed improvements in patients but did not reach statistical significance. The news led to a 43.8% drop in SRPT shares. Roche Holdings AG (OTC: RHHBY) is collaborating with Sarepta on this project.

Portfolio Pulse from Vandana Singh

October 31, 2023 | 12:13 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, a prodrug of psilocin being developed for the treatment of depression and anxiety disorders. The patent, titled 'C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,' includes claims for a family of novel prodrug derivatives of psilocin, including EB-373. The company has filed multiple patent applications for psilocin prodrugs and has submitted additional filings for companion Patent Cooperation Treaty and non-US national patent applications.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:12 pm

SMMT

Summit Therapeutics (NASDAQ:SMMT) announced that data for its novel investigational bispecific antibody, ivonescimab, will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego, CA. The data was generated and analyzed in collaboration with Akeso, Inc. Ivonescimab, known as SMT112 in the United States, Canada, Europe, and Japan, and as AK112 in China and Australia, combines the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Summit has begun its clinical development of ivonescimab in two proposed NSCLC indications.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:12 pm

MRSN

Mersana Therapeutics (NASDAQ:MRSN) announced that the FDA has lifted the clinical hold on the Phase 1 clinical trial of XMT-2056, a systemically administered Immunosynthen STING-agonist ADC designed to target a novel human epidermal growth factor receptor 2 (HER2) epitope. The trial is investigating XMT-2056 in previously treated patients with advanced/recurrent solid tumors expressing HER2. The FDA has granted orphan drug designation to XMT-2056 for the treatment of gastric cancer. In August 2022, Mersana entered into a global collaboration providing GSK plc with an exclusive option to co-develop and commercialize XMT-2056.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:09 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) shares fell in premarket trading on Tuesday, adding to the nearly 5% drop seen on Monday. This is despite U.S. stock futures pointing to a modestly higher open. The immediate trigger could be the China weekly insurance registrations data, which showed a decrease in registrations for Tesla electric vehicles. Future Fund’s Gary Black noted that China-insured registrations totaled 28,400 units, down 22% from the first four weeks of the third quarter. GLJ Research’s Gordon Johnson predicts muted demand for the refreshed Model 3.

Portfolio Pulse from Shanthi Rexaline

October 31, 2023 | 12:09 pm

ALIM

Alimera Sciences, Inc. (NASDAQ:ALIM) announces that clinical data for ILUVIEN, a treatment for diabetic macular edema, will be presented at the American Academy of Ophthalmology's 127th Annual Meeting. The data comes from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:08 pm

CNTA

Centessa Pharmaceuticals has announced the dosing of the first subject in its PRESent-3 study of SerpinPC for the treatment of hemophilia B with inhibitors. The dosing phase follows a 12-week observation period during which baseline data of the subject's disease status under their current therapy are collected. The company began dosing subjects in the PRESent-2 study for the treatment of hemophilia B without inhibitors in July 2023. The FDA has granted Fast Track designation to SerpinPC for the treatment of hemophilia B, with or without inhibitors.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:06 pm

LIFE

aTyr Pharma has announced the dosing of the first patient in its Phase 2 EFZO-CONNECT study. The study will evaluate the efficacy, safety, and tolerability of efzofitimod, a first-in-class biologic immunomodulator, in patients with systemic sclerosis-related interstitial lung disease. The drug has been granted U.S. FDA and EU orphan drug and U.S. FDA Fast Track designations for systemic sclerosis. The study is a 28-week study with three parallel cohorts randomized to either 270 mg or 450 mg of efzofitimod or placebo dosed intravenously monthly for a total of 6 doses.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2023 | 12:05 pm